First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma 

A recent first-in-human phase I study shows the safety and preliminary efficacy of nemtabrutinib in patients with relapsed/refractory B-cell malignancies. These data support further exploration of nemtabrutinib in larger clinical studies.

Categories:

,

Posted on:


Subscribe to our Newsletter

Full Name

Email

Success

Your form submitted successfully!

Error

Sorry! your form was not submitted properly, Please check the errors above.